<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816295</url>
  </required_header>
  <id_info>
    <org_study_id>14396</org_study_id>
    <secondary_id>I5E-MC-TSAT</secondary_id>
    <secondary_id>2012-004866-16</secondary_id>
    <nct_id>NCT01816295</nct_id>
  </id_info>
  <brief_title>A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate if testosterone solution can raise testosterone
      hormone levels into the normal range, and also improve levels of sexual arousal, interest and
      drive and/or energy level, in men with low testosterone and decreased sexual arousal,
      interest and drive and/or decreased energy. The study will last about 16 weeks, followed by
      an optional 24 week open label treatment phase to investigate the long term safety of
      testosterone solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Normal range for total serum testosterone was defined as 300 to 1050 nanograms per deciliter (ng/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Sexual Arousal, Interest, and Drive (SAID) Scale Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SAID Scale is a self-administered instrument used to assess sexual arousal, interest, and sex drive in men with symptomatic hypogonadism. The SAID consists of 5 questions that were scored on a scale from 1 to 5, with &quot;5&quot; corresponding to greater levels of sexual arousal, interest, or drive. The SAID Scale total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater sexual arousal, interest, and drive. Least squares (LS) mean change from baseline was calculated using an analysis of covariance (ANCOVA) with treatment group and the baseline value as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Hypogonadism Energy Diary (HED) Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The HED is a self-administered instrument used to assess real-time energy levels in men with symptomatic hypogonadism. It consists of 2 questions that were scored on a scale from 0 to 10, with &quot;10&quot; corresponding to &quot;Full of Energy&quot; or &quot;Not Tired at All&quot; (The Tiredness scale was reverse-mapped, as it was collected with &quot;10&quot; corresponding to &quot;Extreme Tiredness&quot;). The questionnaire was completed 3 times daily (forming 6 unique items) for 7 consecutive days. Item scores were computed by averaging the values for each item across 7 days. If more than 2 days were missing for an item, the item score was missing. The total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater energy. If any item score was missing, the total score was missing. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Prostate Specific Antigen (PSA) &gt;4 Nanogram/Milliliter (ng/mL)</measure>
    <time_frame>Double Blind Baseline, Week 12, Open Label Baseline, Week 36</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Total International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Baseline, Week 12, Week 36</time_frame>
    <description>The IPSS is a self-administered instrument used to assess for the severity of lower urinary tract symptoms. The IPSS consists of 7 questions that were scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Placebo Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Solution applied topically once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Solution</intervention_name>
    <description>Administered topically to axillae.</description>
    <arm_group_label>Testosterone Solution</arm_group_label>
    <other_name>Axiron</other_name>
    <other_name>Testosterone Solution 2%</other_name>
    <other_name>LY900011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Solution</intervention_name>
    <description>Administered topically to axillae.</description>
    <arm_group_label>Placebo Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total testosterone level &lt;300 nanogram per deciliter (ng/dL) [10.4 nanomole per Liter
             (nmol/L)] at each of 2 screening visits

          -  At least 1 symptom of testosterone deficiency, which must include decreased energy or
             decreased sexual drive

          -  Prostate Specific Antigen (PSA) &lt;4 nanogram per milliliter (ng/ml) at screening

        Exclusion Criteria:

          -  Sexual partner who is or becomes pregnant at any time during the study

          -  Use of long-acting intramuscular (IM) testosterone undecanoate or testosterone pellets
             in the 6-month period prior to screening

          -  Body Mass Index (BMI) &gt;37 kilogram per square meter (kg/m^2) at screening

          -  Severe lower urinary tract symptoms and/or significant prostate enlargement

          -  Prolactin lab test result of &gt;30 ng/mL at screening

          -  Hemoglobin A1c (HbA1c) &gt;11% at screening

          -  Hematocrit ≥50% (&gt;54% at elevated altitude) at screening

          -  Current use of any medications, herbal, and/or nutritional supplements that can
             interfere with testosterone

          -  Dermatologic condition in underarm area that might interfere with testosterone
             absorption (for example, eczema) or be exacerbated by topical testosterone replacement
             therapy

          -  Currently receiving treatment with cancer chemotherapy or antiandrogens

          -  Chronic use of systemic glucocorticoids (use for &gt;14 days within the 3 months prior to
             screening); use of non-testosterone anabolic steroids within 12 months prior to
             screening

          -  Competitive athletes involved in a sport in which they may be screened for anabolic
             steroids

          -  History of use of estrogenizing agents within 12 months prior to screening

          -  History of luteinizing hormone-releasing hormone antagonist or agonist treatment in
             the last 6 months prior to screening

          -  History of clomiphene or other anti-estrogen treatment in the 3 months prior to
             screening

          -  Use of finasteride within 3 months prior to screening, or use of dutasteride within 6
             months prior to screening

          -  Current use of warfarin or phenprocoumon

          -  History of frequent opioid use: &gt;1 time/week during any week within 30 days prior to
             screening

          -  Current use of dopamine receptor agonists (cabergoline, pergolide, bromocriptine)

          -  Have a history of significant central nervous system injuries or disease (including
             stroke, spinal cord injury, or multiple sclerosis) within 6 months prior to screening

          -  Systolic blood pressure &gt;170 or &lt;90 millimeter of mercury (mm Hg) or diastolic blood
             pressure &gt;100 or &lt;50 mm Hg at screening or a history of malignant hypertension

          -  History of unstable angina as defined by Braunwald Classification of Unstable Angina
             or angina occurring during sexual intercourse in the last 6 months

          -  History of any of the following coronary conditions within 90 days of screening:
             myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary
             intervention (angioplasty or stent placement)

          -  Have any supraventricular arrhythmia with an uncontrolled ventricular response [mean
             heart rate &gt;100 beats per minute (bpm)] at rest, or have any history of spontaneous or
             induced sustained ventricular tachycardia (heart rate &gt;100 bpm for ≥30 seconds), or
             use of an automatic internal cardioverter-defibrillator

          -  Have a history of sudden cardiac arrest

          -  Exhibit any evidence of congestive heart failure [New York Heart Association (NYHA)
             Class 2 or above], within 6 months prior to screening

          -  Have had a new, significant cardiac conduction defect within 90 days prior to
             screening

          -  Clinical suspicion (or history) of prostate cancer during digital rectal examination
             at screening

          -  Known or suspected breast cancer (or history of breast cancer) or other active cancer
             (with the exception of nonmelanotic skin cancer)

          -  Exhibit evidence of severe renal impairment [creatinine clearance &lt;30 milliliter per
             minute (mL/min) as determined by the Cockcroft-Gault formula] at screening

          -  Exhibit a history of severe liver disease or clinical evidence of hepatic impairment
             at screening

          -  Have a history of human immunodeficiency virus (HIV) infection

          -  Severe sleep apnea

          -  Untreated hypothyroidism, hypercortisolism or other significant endocrinopathy (other
             than hypogonadism) that contributes to symptoms of low energy or fatigue
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hettstedt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Holzminden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jeon Ju-City</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kwang Ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aravaca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coslada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hathersage Road</city>
        <state>Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <results_first_submitted>September 1, 2015</results_first_submitted>
  <results_first_submitted_qc>September 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2015</results_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Solution</title>
          <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Testosterone Solution</title>
          <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OLE Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275">Participants who completed the DBP and still met eligibility criteria had option to enroll in OLE.</participants>
                <participants group_id="P2" count="283">Participants who completed the DBP and still met eligibility criteria had option to enroll in OLE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Solution</title>
          <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Testosterone Solution</title>
          <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="357"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="715"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="11.35"/>
                    <measurement group_id="B2" value="54.7" spread="10.58"/>
                    <measurement group_id="B3" value="55.3" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>East Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilogram per square meter (kg/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="4.21"/>
                    <measurement group_id="B2" value="30.3" spread="4.06"/>
                    <measurement group_id="B3" value="30.6" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptoms of Hypogonadism</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Only Low Energy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only Decreased Sexual Drive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Symptoms Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12</title>
        <description>Normal range for total serum testosterone was defined as 300 to 1050 nanograms per deciliter (ng/dL).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who completed 12 weeks of treatment and had non-missing testosterone concentration at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Solution</title>
            <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Solution</title>
            <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12</title>
          <description>Normal range for total serum testosterone was defined as 300 to 1050 nanograms per deciliter (ng/dL).</description>
          <population>All randomized participants who completed 12 weeks of treatment and had non-missing testosterone concentration at week 12.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Sexual Arousal, Interest, and Drive (SAID) Scale Scores</title>
        <description>The SAID Scale is a self-administered instrument used to assess sexual arousal, interest, and sex drive in men with symptomatic hypogonadism. The SAID consists of 5 questions that were scored on a scale from 1 to 5, with &quot;5&quot; corresponding to greater levels of sexual arousal, interest, or drive. The SAID Scale total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater sexual arousal, interest, and drive. Least squares (LS) mean change from baseline was calculated using an analysis of covariance (ANCOVA) with treatment group and the baseline value as covariates.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who reported low sex drive at baseline with non-missing SAID Scale data at baseline and at least one post baseline visit. Missing data endpoints were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Solution</title>
            <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Solution</title>
            <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Sexual Arousal, Interest, and Drive (SAID) Scale Scores</title>
          <description>The SAID Scale is a self-administered instrument used to assess sexual arousal, interest, and sex drive in men with symptomatic hypogonadism. The SAID consists of 5 questions that were scored on a scale from 1 to 5, with &quot;5&quot; corresponding to greater levels of sexual arousal, interest, or drive. The SAID Scale total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater sexual arousal, interest, and drive. Least squares (LS) mean change from baseline was calculated using an analysis of covariance (ANCOVA) with treatment group and the baseline value as covariates.</description>
          <population>Randomized participants who reported low sex drive at baseline with non-missing SAID Scale data at baseline and at least one post baseline visit. Missing data endpoints were imputed using last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.99"/>
                    <measurement group_id="O2" value="11.4" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.42</dispersion_value>
            <ci_percent>99.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>9.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Hypogonadism Energy Diary (HED) Scores</title>
        <description>The HED is a self-administered instrument used to assess real-time energy levels in men with symptomatic hypogonadism. It consists of 2 questions that were scored on a scale from 0 to 10, with “10” corresponding to &quot;Full of Energy&quot; or &quot;Not Tired at All&quot; (The Tiredness scale was reverse-mapped, as it was collected with “10” corresponding to &quot;Extreme Tiredness&quot;). The questionnaire was completed 3 times daily (forming 6 unique items) for 7 consecutive days. Item scores were computed by averaging the values for each item across 7 days. If more than 2 days were missing for an item, the item score was missing. The total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater energy. If any item score was missing, the total score was missing. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Randomized participants who reported low energy at baseline with non-missing HED questionnaire at baseline and at least one post baseline visit. Missing data endpoints were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Solution</title>
            <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Solution</title>
            <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Hypogonadism Energy Diary (HED) Scores</title>
          <description>The HED is a self-administered instrument used to assess real-time energy levels in men with symptomatic hypogonadism. It consists of 2 questions that were scored on a scale from 0 to 10, with “10” corresponding to &quot;Full of Energy&quot; or &quot;Not Tired at All&quot; (The Tiredness scale was reverse-mapped, as it was collected with “10” corresponding to &quot;Extreme Tiredness&quot;). The questionnaire was completed 3 times daily (forming 6 unique items) for 7 consecutive days. Item scores were computed by averaging the values for each item across 7 days. If more than 2 days were missing for an item, the item score was missing. The total score was computed by summing the item scores and linearly transforming the sum to a 0 to 100 scale, with higher scores corresponding to greater energy. If any item score was missing, the total score was missing. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
          <population>Randomized participants who reported low energy at baseline with non-missing HED questionnaire at baseline and at least one post baseline visit. Missing data endpoints were imputed using LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="0.87"/>
                    <measurement group_id="O2" value="10.5" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>99.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>6.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Total International Prostate Symptom Score (IPSS)</title>
        <description>The IPSS is a self-administered instrument used to assess for the severity of lower urinary tract symptoms. The IPSS consists of 7 questions that were scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
        <time_frame>Baseline, Week 12, Week 36</time_frame>
        <population>All randomized participants with non-missing baseline IPSS measurement and at least one non-missing post baseline IPSS measurement. Missing data endpoints were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Solution</title>
            <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Solution</title>
            <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total International Prostate Symptom Score (IPSS)</title>
          <description>The IPSS is a self-administered instrument used to assess for the severity of lower urinary tract symptoms. The IPSS consists of 7 questions that were scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean change from baseline was calculated using ANCOVA with treatment group and the baseline value as covariates.</description>
          <population>All randomized participants with non-missing baseline IPSS measurement and at least one non-missing post baseline IPSS measurement. Missing data endpoints were imputed using LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.24"/>
                    <measurement group_id="O2" value="-0.9" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 36 (n=247, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.28"/>
                    <measurement group_id="O2" value="-0.7" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline to Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.442</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline to Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Prostate Specific Antigen (PSA) &gt;4 Nanogram/Milliliter (ng/mL)</title>
        <time_frame>Double Blind Baseline, Week 12, Open Label Baseline, Week 36</time_frame>
        <population>All participants with non-missing PSA result at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Solution</title>
            <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period. In optional open label extension (OLE) period, 60 milligram (mg) testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Solution</title>
            <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period. Optional OLE period starting at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Prostate Specific Antigen (PSA) &gt;4 Nanogram/Milliliter (ng/mL)</title>
          <population>All participants with non-missing PSA result at the specified time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-Blind Baseline (n=350, 347)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=289, 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label Baseline (n=269, 278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=219, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Analysis population includes all evaluable, randomized patients who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Solution - Double Blind</title>
          <description>Placebo solution applied topically to axillae once daily for 12 week double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Testosterone Solution - Double Blind</title>
          <description>Sixty mg testosterone solution applied topically to axillae once daily with possible down/up titration (30 – 120 mg/day) for 12 week double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Testosterone Solution - OLE</title>
          <description>Sixty mg testosterone solution applied topically to axillae once daily at 60 mg/day with possible down/up titration (30 – 120 mg/day) for 24 weeks in optional OLE period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="252" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gingival cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Salivary duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Application site pustules</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erythema induratum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasal vestibulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="356"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="354"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="354"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood follicle stimulating hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood insulin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood luteinising hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood testosterone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Electrocardiogram p wave abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematocrit increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="354"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>High density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mean cell volume increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Red blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vitamin b complex deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="354"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="354"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sleep phase rhythm disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Trigeminal nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Writer's cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Premature ejaculation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Genital paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Painful erection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Spermatic cord pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Testicular atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hair growth abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="354"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="356"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sexual activity increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Substance use</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Corneal transplant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>High frequency ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Orthodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Posterior lens capsulotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Suture insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vasectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wisdom teeth removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="354"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

